Technical Analysis for KOD - Kodiak Sciences Inc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 3.28 | 2.98% | 0.10 |
Earnings due: May 13
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | 2.98% | |
| Narrow Range Bar | Range Contraction | 2.98% | |
| Wide Bands | Range Expansion | 2.98% | |
| Oversold Stochastic | Weakness | 2.98% | |
| Spinning Top | Other | -2.96% | |
| Narrow Range Bar | Range Contraction | -2.96% | |
| Wide Bands | Range Expansion | -2.96% | |
| Oversold Stochastic | Weakness | -2.96% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 23 hours ago |
| Up 5% | about 23 hours ago |
| Up 3% | about 23 hours ago |
| Fell Below Lower Bollinger Band | about 23 hours ago |
| Up 2% | about 23 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/13/2024
Kodiak Sciences Inc Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidate include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases. The company's early research pipeline include KSI-601, a triplet inhibitor for dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Inflammation Ophthalmology Macular Degeneration Vascular Disease Diabetic Retinopathy Retina Wet Age Related Macular Degeneration Retinopathy Preclinical Stage Product Angiogenesis Angiology Retinal Disease Retinal Diseases Vascular Endothelial Growth Factor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.79 |
| 52 Week Low | 1.37 |
| Average Volume | 838,063 |
| 200-Day Moving Average | 3.45 |
| 50-Day Moving Average | 5.09 |
| 20-Day Moving Average | 3.91 |
| 10-Day Moving Average | 3.48 |
| Average True Range | 0.38 |
| RSI (14) | 32.89 |
| ADX | 29.96 |
| +DI | 15.49 |
| -DI | 33.01 |
| Chandelier Exit (Long, 3 ATRs) | 6.63 |
| Chandelier Exit (Short, 3 ATRs) | 4.31 |
| Upper Bollinger Bands | 4.84 |
| Lower Bollinger Band | 2.97 |
| Percent B (%b) | 0.16 |
| BandWidth | 47.91 |
| MACD Line | -0.54 |
| MACD Signal Line | -0.49 |
| MACD Histogram | -0.0508 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.58 | ||||
| Resistance 3 (R3) | 3.58 | 3.47 | 3.53 | ||
| Resistance 2 (R2) | 3.47 | 3.40 | 3.48 | 3.51 | |
| Resistance 1 (R1) | 3.38 | 3.35 | 3.43 | 3.38 | 3.50 |
| Pivot Point | 3.27 | 3.27 | 3.30 | 3.28 | 3.27 |
| Support 1 (S1) | 3.18 | 3.20 | 3.23 | 3.18 | 3.06 |
| Support 2 (S2) | 3.07 | 3.15 | 3.08 | 3.05 | |
| Support 3 (S3) | 2.98 | 3.07 | 3.03 | ||
| Support 4 (S4) | 2.98 |
